cgi-1746 and Neoplasms

cgi-1746 has been researched along with Neoplasms* in 1 studies

Reviews

1 review(s) available for cgi-1746 and Neoplasms

ArticleYear
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Bruton's tyrosine kinase (BTK) regulates multiple important signaling pathways and plays a key role in the proliferation, survival, and differentiation of B-lineage cells and myeloid cells. BTK is a promising target for the treatment of hematologic malignancies. Ibrutinib, the first-generation BTK inhibitor, was approved to treat several B-cell malignancies. Despite the remarkable potency and efficacy of ibrutinib against various lymphomas and leukemias in the clinics, there are also some clinical limitations, such as off-target toxicities and primary/acquired drug resistance. As strategies to overcome these challenges, second- and third-generation BTK inhibitors, BTK-PROTACs, as well as combination therapies have been explored. In this review, we summarize clinical developments of the first-, second- and third-generation BTK inhibitors, as well as recent advances in BTK-PROTACs and ibrutinib-based combination therapies.

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Cyclin-Dependent Kinase 4; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Immunotherapy; Neoplasms; Piperidines; Protein Kinase Inhibitors

2022